⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16212232 | 1.00 | — | — | |
| SCHEMBL1458711 | 1.00 | — | — | |
| Formic Acid SCHEMBL31336082 | 0.92 | — | — | |
| Fumaric Acid SCHEMBL1756130 | 0.88 | TSHR (0.41) | — | |
| Maleic Acid SCHEMBL1756123 | 0.88 | TSHR (0.41) | — | |
| Malic Acid SCHEMBL22367533 | 0.77 | SMN1; SMN2 (0.52) | — | |
| Citric Acid SCHEMBL22367547 | 0.77 | ALDH1A1 (0.52) | — | |
| SCHEMBL15711047 | 0.74 | GRIK1 (0.31) | — | |
| SCHEMBL22344706 | 0.74 | — | — | |
| SCHEMBL9319818 | 0.74 | GRIK1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331023-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2025-06-17 | — | — | US | claimed |
| US-20240277722-A1 | CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-CANCER AGENT | AURIGENE ONCOLOGY LTD (IN) | 2024-08-22 | — | — | US | claimed |
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC. (KR) | 2024-07-25 | — | — | US | claimed |
| WO-2024064091-A1 | NOVEL PYRIMIDINE COMPOUND AS KINASE INHIBITORS WITH BIOLOGICAL ACTIVITIES ON EGFR MUTANTS | Advenchen Pharmaceuticals, LLC (US) | 2024-03-28 | — | — | WO | claimed |
| US-20240016811-A1 | CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-MICROTUBULE AGENT | AURIGENE ONCOLOGY LIMITED (IN) | 2024-01-18 | — | — | US | claimed |
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | US | claimed |
| US-20220098156-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-03-31 | — | — | US | claimed |
| CN-108341873-B | Antibodies to epidermal growth factor receptor 3(HER3) | 诺华股份有限公司 | 2022-03-25 | — | — | CN | claimed |
| US-11174232-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-11-16 | — | — | US | claimed |
| EP-3737404-A1 | SELECTIVE TARGETING OF APOPTOSIS PROTEINS BY STRUCTURALLY-STABILIZED AND/OR CYSTEINE-REACTIVE NOXA PEPTIDES | Dana Farber Cancer Institute, Inc. (US) | 2020-11-18 | — | — | EP | claimed |
| US-20200262793-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2020-08-20 | — | — | US | claimed |
| WO-2019118719-A1 | SELECTIVE TARGETING OF APOPTOSIS PROTEINS BY STRUCTURALLY-STABILIZED AND/OR CYSTEINE-REACTIVE NOXA PEPTIDES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-20 | — | — | WO | claimed |
| EP-3302448-A1 | SUBSTITUTED HETEROCYCLYL DERIVATIVES AS CDK INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2018-04-11 | — | — | EP | claimed |
| WO-2016193939-A1 | SUBSTITUTED HETEROCYCLYL DERIVATIVES AS CDK INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-12-08 | — | — | WO | claimed |
| WO-2009151910-A2 | COMBINATION PRODUCT OF RECEPTOR TYROSINE KINASE INHIBITOR AND FATTY ACID SYNTHASE INHIBITOR FOR TREATING CANCER | WYETH (US) | 2009-12-17 | — | — | WO | claimed |
| US-20080300248-A1 | Quinazoline Derivatives, Preparation Methods and Uses Thereof | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2008-12-04 | — | — | US | claimed |
| EP-4720038-A1 | (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES | Neophore Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-1117659-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | American Cyanamid Company (US) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018761-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-04-06 | — | — | WO | disclosed |